AcquisitionOther
DICE Therapeutics, Inc. acquired DICE Therapeutics to Advance Innovation
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
DICE Therapeutics, Inc. -> DICE Therapeutics to Advance Innovation · $48
DICE is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.
Open source record (SEC) ↗